ZYXI - Zynex, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.9600
+0.0100 (+0.20%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close4.9500
Open4.9900
Bid0.40 x 2200
Ask5.25 x 800
Day's Range4.9400 - 4.9900
52 Week Range2.4000 - 5.4300
Volume48,156
Avg. Volume23,211
Market Cap160.727M
Beta (3Y Monthly)1.90
PE Ratio (TTM)16.64
EPS (TTM)0.30
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-12-31
1y Target Est6.92
Trade prices are not sourced from all markets
  • Zynex to Ring the Nasdaq Stock Market Opening Bell to Celebrate Its Listing
    PR Newswire2 days ago

    Zynex to Ring the Nasdaq Stock Market Opening Bell to Celebrate Its Listing

    The ceremony commemorates Zynex's listing on the Nasdaq Capital Market on February 21, 2019. Thomas Sandgaard, Founder, Chairman and CEO is pleased to celebrate alongside Zynex's Board of Directors and members of the executive team honoring the Company's milestone achievement.

  • Should You Be Holding Zynex, Inc. (NASDAQ:ZYXI)?
    Simply Wall St.2 days ago

    Should You Be Holding Zynex, Inc. (NASDAQ:ZYXI)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires lookingRead More...

  • Zynex Announces Uplisting to The Nasdaq Capital Market
    PR Newswire8 days ago

    Zynex Announces Uplisting to The Nasdaq Capital Market

    ENGLEWOOD, Colo., Feb. 7, 2019 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, is pleased to announce that its common shares have been approved to list on The Nasdaq Capital Market and is expected to begin trading under its existing symbol (ZYXI) on February 12, 2019. "We are excited to reach this important milestone for Zynex.

  • ACCESSWIRE3 months ago

    Zynex to Present at the 11th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 20, 2018 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it will be presenting at the 11th annual LD Micro Main Event on Tuesday, December 4th at 4:30pm PST / 7:30pm EST. Zynex's CEO, Thomas Sandgaard will be presenting and meeting with investors. The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ZYXI earnings conference call or presentation 6-Nov-18 4:00pm GMT

    Q3 2018 Zynex Inc Earnings Call

  • Zynex Announces 2018 Third Quarter Earnings and Special Dividend
    PR Newswire3 months ago

    Zynex Announces 2018 Third Quarter Earnings and Special Dividend

    - Revenue increased 19% year over year to $8.1 million - Net income of $2.6 million increased 18% year over year; Diluted EPS $0.08 - Adjusted EBITDA of $3.0 million - Board of Directors declares a one-time ...

  • Zynex Schedules 2018 Third Quarter Earnings Release and Webcast
    PR Newswire3 months ago

    Zynex Schedules 2018 Third Quarter Earnings Release and Webcast

    ENGLEWOOD, Colo. , Nov. 2, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • Zynex Obtains U.S. Patent for Blood Volume Monitor
    PR Newswire4 months ago

    Zynex Obtains U.S. Patent for Blood Volume Monitor

    ENGLEWOOD, Colo., Oct. 8, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announces that it has obtained a U.S. utility patent for its Blood Volume Monitor Device. Thomas Sandgaard, the inventor, has assigned the patent to Zynex's subsidiary, Zynex Monitoring Solutions.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ZYXI earnings conference call or presentation 8-May-18 3:00pm GMT

    Q1 2018 Zynex Inc Earnings Call

  • Zynex to Present at the Ladenburg Thalmann 2018 Healthcare Conference
    PR Newswire5 months ago

    Zynex to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    ENGLEWOOD, Colo., Sept. 25, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, and neurological diagnostics, today announced that Thomas Sandgaard, Chief Executive Officer of Zynex, will be presenting at the Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday October 2, 2018 at 2:30 pm EDT.  The conference will be held at the Sofitel Hotel in New York City.

  • Zynex to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
    PR Newswire6 months ago

    Zynex to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    Thomas Sandgaard, Chief Executive Officer of Zynex, will provide an overview of the Company's business in a presentation scheduled on Thursday, September 6, 2018 at 12:05 pm EDT. Management will also be meeting with members of the investment community during one-on-one meetings.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of ZYXI earnings conference call or presentation 2-Aug-18 5:00pm GMT

    Q2 2018 Zynex Inc Earnings Call

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on Zynex, Inc.

    NEW YORK, NY / ACCESSWIRE / August 16, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

  • ACCESSWIRE6 months ago

    Consilium Global Research Issues Quarterly Update on Zynex, Inc (OTCQB: ZYXI)

    ST. PETERSBURG, FL / ACCESSWIRE / August 10, 2018 / Consilium Global Research (CGR) an Investor Recognition Company that connects Companies with Investors, today announced that it has issued an Update ...

  • Zynex Announces 2018 Second Quarter Earnings
    PR Newswire7 months ago

    Zynex Announces 2018 Second Quarter Earnings

    - Revenue increased 50% year over year to $7.6 million - Net income of $2.4 million increased 61% year over year; Diluted EPS $0.07 - Adjusted EBITDA of $2.8 million increased 41% year over year - Eighth ...

  • Zynex Schedules 2018 Second Quarter Earnings Release and Webcast
    PR Newswire7 months ago

    Zynex Schedules 2018 Second Quarter Earnings Release and Webcast

    LONE TREE, Colo. , July 27, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • Zynex Recognized in Top 100 Public Companies by ColoradoBiz
    PR Newswire9 months ago

    Zynex Recognized in Top 100 Public Companies by ColoradoBiz

    ENGLEWOOD, Colo., May 23, 2018 /PRNewswire/ -- Zynex (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurodiagnostic equipment, today announced that ColoradoBiz Magazine has recognized Zynex as a Top100 Public Company in its May/June 2018 issue. Zynex was ranked 83rd on 2017 revenue of $23.4 million up from 90th in 2016 on $13.3 million in revenue. For over 45 years, state officials, company executives and business professionals have looked to ColoradoBiz as the statewide voice of our business community.

  • Zynex Announces Share Buyback Program
    PR Newswire9 months ago

    Zynex Announces Share Buyback Program

    ENGLEWOOD, Colo., May 14, 2018 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back an additional $2 million of the Company's common stock.  The new program will commence on May 14, 2018 and is scheduled to terminate on May 13, 2019 or when the $2 million buyback limit is reached. The Company previously re-purchased 495,091 shares of its common stock under a prior buyback program from December 6, 2017 through March 6, 2018. In making the announcement, Zynex President and CEO Thomas Sandgaard stated, "We are committed to delivering shareholder value, and this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy.

  • Zynex Announces 2018 First Quarter Earnings
    PR Newswire9 months ago

    Zynex Announces 2018 First Quarter Earnings

    - Revenue grew 100% year over year to $6.9 million - Net income of $1.9 million increased 444% year over year; Diluted EPS $0.06 - Adjusted EBITDA of $2.0 million increased 257% year over year - Seventh ...

  • Zynex Schedules 2018 First Quarter Earnings Release and Webcast
    PR Newswire10 months ago

    Zynex Schedules 2018 First Quarter Earnings Release and Webcast

    LONE TREE, Colo. , May 1, 2018 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire11 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...